PARIS, FRANCE, March 26, 2025 -- Altis Labs, Inc. (“Altis”) is announcing results presented at the European Lung Cancer Congress (ELCC) 2025 in Paris: at 8 weeks, IPRO-Δ predicted overall survival differences similarly to treatment discontinuation status at 16 weeks in advanced non-small cell lung cancer (aNSCLC) patients.
In this evaluation, IPRO-Δ was assessed in a real-world cohort of 154 aNSCLC patients with both a pre-treatment baseline (BL) and follow up CT scan at 8 weeks (± 4 weeks) after first-line (1L) treatment initiation. Altis’ AI pipeline was applied to pairs of Baseline and Week 8 CT scans to generate IPRO-Δ survival scores. The association of 1L-Tx status at four months was compared using Kaplan-Meier survival analyses to the corresponding IPRO-Δ thresholds, with OS landmarked at 90 days.
By anticipating survival differences early, IPRO-Δ helps measure treatment effects in clinical trials.
Dr. Omar F. Khan, a medical oncologist from Tom Baker Cancer Center, University of Calgary, presented the results at ELCC.
Access the ePoster here.
About Altis Labs
Altis Labs is the computational imaging company accelerating clinical trials with AI.
Altis has created the industry's largest real-world Imaging, Clinical, and Outcomes database – comprising over 210 million cancer patient images linked to associated demographic, diagnostic, molecular, treatment, and survival information. Deep learning models trained on rwICO can generate profound insights beyond tumor measurements that make up reductionist criteria like RECIST 1.1, yielding greater association with overall survival.
Top 20 biopharma sponsors apply our deep learning models to their clinical trial imaging data to unlock powerful insights. Our models instantaneously generate Imaging-based Prognostication (IPRO) scores and thousands of Spatial Imaging Biomarkers (SIBs) from each scan, which Sponsors can combine for analysis with other data modalities such as ctDNA. These insights are being explored by clinical development teams to quantify treatment effects earlier in order to design more successful clinical trials.
Our multi-disciplinary team is on a mission to help get the most effective novel treatments to patients sooner. Altis is proudly headquartered in Toronto, Canada.
To learn more, email info@altislabs.com.